TwitterLinkedin

Contact Us

  • News & Events
    • News
    • Webinars
    • Events
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Working at PharmaLex
    • Your Application Process
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Our Milestones
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Development Strategy and Gap Analysis
            • Integrated Product Development
            • Market Access Strategy
            • Non-clinical Development Concept
              and Study Design
            • Scientific Advice
            • Scientific Due Diligence
            • Statistical Services
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Orphan Drug Designation
            • Pediatric Investigation Plan (PIP)
            • Scientific Advice
            • Statistical Services
          • Regulatory Affairs

            • Clinical Trial Applications (CTA)
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • IMP Management
            • Interim / Contract QA
            • Quality Systems
            • Tech Transfer / Scale-up
            • Vendor Management and Oversight
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistical Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Environmental Risk Assessment
            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • Audit and CAPA Management
            • EU QPPV / National QPPV
            • ICSR Management
            • Literature Screening
            • Pharmacovigilance Systems
            • Safety Writing (PSUR, RMP)
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • Good Distribution Practice (GDP) Compliance
            • GxP Services
            • Interim / Contract QA
            • Quality Systems
            • Vendor Audit
            • Vendor Management and Oversight
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
            • Medical Information
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • Consulting
            • Consumer Healthcare
            • Generics
            • Herbal Medicines
            • Medicinal Products
            • MedTech Services
            • Pharmaceutical
            • Veterinary Drugs
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • Brexit
            • COVID-19 Support
            • Drug Re-purposing / Value-added Medicines
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Statistical Services
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • News
    • Webinars
    • Events
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Working at PharmaLex
    • Your Application Process
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Quality Considerations for Manufacturing in Pharma

Quality Considerations for Manufacturing in Pharma

Quality Considerations for Continuous Manufacturing in the Pharmaceutical Industry

The FDA issued a draft guidance document  in February 2019 titled “Quality Considerations for Continuous Manufacturing, Guidance for Industry”. This guidance document contains information regarding the FDA’s current thinking on the quality considerations for continuous manufacturing of small-molecule and solid oral drug products. It is important to understand that this draft guidance document is currently in the ninety day consultation and review period. It has not yet been approved for implementation.

It outlines that the benefits associated with continuous manufacturing mean that the manufacturing process will ultimately result in an integrated manufacturing process with fewer steps and shorter processing times. If implemented correctly a continuous manufacturing process would provide the following benefits:

  • Smaller equipment footprint
  • Supporting an enhanced development approach (e.g., Quality by Design (QbD), use of Process Analytical Technology (PAT) and models)
  • Real-time product quality monitoring
  • Flexible operation to allow scale-up, scale-down, and scale-out to accommodate changing supply demands

The output of these improvements would ultimately reduce the number of drug product quality issues, lower manufacturing costs, and improve availability of quality medicines to patients.

Some key concepts of a continuous manufacturing process include the following:

Process Dynamics:

An understanding of process dynamics is essential for the identification and mitigation of risks to product quality. The different elements associated with process dynamics range from the input material attributes to process conditions to equipment design elements both during and after production. As a result of the dynamic nature of a continuous manufacturing process the risk assessment should consider process understanding of the integrated system in addition to each unit operation.

Control Strategy:

A Control Strategy is a key quality aspect to the successful implementation of continuous manufacturing. Establishing, maintaining, and refining a control strategy is a life cycle activity – from development to technology transfer to ongoing verification during the commercial manufacturing phase. An effective PQS strengthens the links across the stages of a product’s life cycle and enables the development and continuous improvement of the control strategy. Key elements of a control strategy include;

  • Control of input materials
  • Process Monitoring and Control
  • Material Diversion
  • Real Time release testing
  • Specification
  • Equipment
  • System Integration, Data Processing and Management

Process Validation:

The ability to evaluate real time data to maintain operations within established criteria to produce drug products with a high degree of assurance of meeting all the attributes they are intended to possess is an integral element of process validation. For the successful validation of a continuous manufacturing process, the FDA recommends that the following guidelines are incorporated:

  • Process Validation: General Principles and Practices
  • ICH Q8 Pharmaceutical Development
  • ICH Q9Quality Risk Management
  • ICH Q10Pharmaceutical Quality System
  • FDA’s three-phase model (1 Process Design; 2 Process Qualification; 3 Continued Process Verification)

Additional Pharmaceutical Quality System Considerations:

The guidance document also recommends that manufacturers should re-examine their quality management systems to ensure that is robust enough and covers the new challenges that continuous manufacturing presents such as handling process failures in real time, review of raw materials, change management and CAPA. An appropriate level of continuous manufacturing expertise in area such as quality, manufacturing operations and regulatory affairs should also be established, and training plans put in place where appropriate.

Scale Up:

Scale up is possible in three ways – increasing run time with no change to mass flow rate, increasing the mass flow rate or increasing both. Each method of scale up should be carefully examined to identify and assess risks. An advantage of continuous manufacturing is that the equipment used for process development can also be used for commercial manufacturing. Any scale up activities must be appropriately evaluated in the company’s change management process.

Stability:

As outlined in guidance for industry ICH Q1A(R2) Stability Testing of New Drug Substances and Products (https://www.ema.europa.eu/en/ich-q1a-r2-stability-testing-new-drug-substances-drug-products), data from stability studies should be provided on at least three primary batches of the drug product, and where possible, these should be manufactured by using different batches of the drug substance. Alternatively, stability samples could be obtained from a single continuous manufacturing campaign where manufacturing variability is captured (e.g., by introducing different batches of input material(s) in a sequential manner).

 

Bridging existing batch to continuous manufacturing:

As a change from batch to continuous manufacturing would result in a change in the scientific operating principle, the most appropriate filing strategy would be a Prior Approval Supplement (PAS). The FDA encourage any Manufacturers wishing to implement Continuous Manufacturing to discuss changes and bridging strategies to gain feedback prior to conducting any studies.

The continuous manufacturing draft guideline can be found on the FDA website: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM632033.pdf

If you would like more information on how PharmaLex can support you with the implementation of the different key concepts of a continuous manufacturing process please contact us on +353 1 846 4742 or contactirl@pharmalex.com.

Related posts
mepharma partnership pharmalex
New Partnership Announcement for MEPHARMA and PharmaLex
21st January 2021
fda webinar
What you need to know to submit Study Data to FDA
19th January 2021
SMARTRISK
SMARTRISK – risk assessment excipient tool
12th January 2021
medical devices digital health era
Medical Devices in the Digital Health Era
10th December 2020
medicinal cannabis
Medicinal Cannabis: The Wonder Substance
1st December 2020
Regulatory Challenges in the COVID Era
1st December 2020
Search
Upcoming Webinars

January 26th, 2021

Unlocking BLA, NDA, IND Submissions

5 PM CET

February 2nd, 2021

Central American Regulation for Drug Products (LATAM)

3 PM CET

February 25th, 2021

What you need to know to submit Study Data to FDA

5PM CET

Upcoming Events

March 22 - January 25th, 2021

BIO Europe Spring 2021

Visit us at booth Virtual

February 8 - 10th, 2021

DIA RSIDM 2021

Visit us at booth Virtual

March 15 - 19th, 2021

DIA Europe 2021

June 14 - 17th, 2021

BIO International Convention 2021

June 27 - July 1st, 2021

DIA Annual Meeting 2021

September 22 - 24th, 2021

TOPRA Symposium 2021

Categories
  • All News
  • Webinars
  • Events
Archive
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
Tweets by @PharmaLexGLOBAL
COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • PharmaLex is dedicated to delivering a comprehensive portfolio while their modular approach allows tailor-made solutions. They acknowledge our feedback, modify their approach and adapt accordingly.

    Top 10 Pharma Company
    President
PharmaLex
©2021 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit Logo

#AskTheExpert #TogetherBEYONDCOVID19





    Select your state:

    .
    You can unsubscribe at any time at data.protection@pharmalex.com

    If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

    #TogetherBEYONDCOVID19

    We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for

      Please DO NOT send us event/conference information.
      We will not respond and these will be deleted immediately.





      Select your state:

      .
      You can unsubscribe at any time at
      data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      Privacy Policy

      This can be specific information about signing up to the newsletter.

      Pellentesque lobortis, tellus at ultrices ullamcorper, lectus tellus consectetur lectus, id consequat leo quam quis eros. Mauris pellentesque tortor a augue pellentesque ultricies. Phasellus sit amet suscipit orci, vel dapibus ligula. Maecenas at pellentesque lectus, sit amet tristique felis. Integer fringilla risus ac neque mollis, at imperdiet lacus sodales. In vehicula orci sed vulputate interdum. Nunc sagittis non nunc eget sollicitudin.

      Maecenas a mattis erat. Phasellus cursus erat non nisl pulvinar ultricies. Aenean id fringilla libero. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Morbi in ultrices elit. Suspendisse egestas hendrerit est. Integer pellentesque nisl ut justo tempus, nec suscipit dolor luctus. Cras vestibulum elementum tincidunt.

      In compliance with the Spanish Law 15/1999, of Protection of Personal Data and in accordance with regulations approved by the Spanish RD 994/1999 inform you that your data will be part of a file located in Friedrichsdorf (Germany), whose ownership belongs to Pharmalex Spain S.L.U. The purpose of these data is the insertion in a potential job selection process. Inform the user that at any time may exercise their right of access, rectification, and deletion of data through email curriculum@pharmalex.com or to this postal address Pharmalex Spain. Coso 103, 50001 Zaragoza, Spain.